Imaging and interoperability solutions provider
Merge Healthcare Incorporated
) has extended its customer base as it seeks to provide its
complete cardiology solutions suite to Arnot Ogden Medical
Center, a member of Arnot Health.
MEDASSETS INC (MDAS): Free Stock Analysis
MEDICAL ACTION (MDCI): Free Stock Analysis
MERGE HEALTHCAR (MRGE): Free Stock Analysis
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The Merge cardiology suite consists of Merge Cardio and Merge
Hemo. While Merge Cardio is an enterprise level image and
information system which delivers a patient's complete cardio
record across all cardiac modalities, Merge Hemo automates the
cath lab process into an electronic record to enable automated
reporting. In Dec 2012, Merge Hemo was selected as Category
Leader in the Best in KLAS Awards for 2012 in the realm of
Software and Services for Cardiology Hemodynamics. This marked
the second year that Merge's offering has won this award.
The deployment of Merge's solutions at Arnot Ogden will enable
the latter to improve standards of care as it will capture,
manage and display multi-modality cardiac images and hemodynamics
and ECG data across the enterprise. The implementation of the
complete cardiology suite will increase image access and exchange
while decreasing healthcare costs at Arnot Ogden.
Management at Arnot Ogden assert that the deployment of Merge
Cardio will enhance workflow efficacy and improve time management
for physicians. Further, the implementation of Merge Hemo is
expected to augment quality control, helped by upgraded
It is commendable that Merge has effectively expanded its client
base amid a tough reimbursement environment for advanced medical
imaging. We are also encouraged by the impressive growth in
recent quarters on the back of client wins despite the general
slowdown in hospital spending and low demand for imaging
equipment and related technology.
Going forward, we are bullish on Merge as it has immense
potential in the diagnostic imaging market. As a result, the
stock carries a Zacks Rank #2 (Buy). Besides Merge, medical
), carrying a Zacks Rank #1 (Strong Buy) are expected to do well
in the near term.